Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results ...

Earnings Estimate Revisions for Nevro For the fiscal year ending December 2024, this maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share, which is a ...

Wolfe upgraded Nevro to Peer Perform from Underperform but removed its $14 price target. More on Johnson & Johnson, Nevro, ...

Nevro NVRO recently announced preliminary revenues for fourth-quarter and full year 2024. Investors seem to panic eyeing the preliminary results, as the company’s shares declined nearly 8% at ...

REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its technological innovations and diversification plans regarding its product portfolio. The optimism, led by a solid ...